Vaneck Pharmaceutical Etf Price To Earning
| PPH Etf | USD 90.14 0.13 0.14% |
VanEck Pharmaceutical ETF fundamentals help investors to digest information that contributes to VanEck Pharmaceutical's financial success or failures. It also enables traders to predict the movement of VanEck Etf. The fundamental analysis module provides a way to measure VanEck Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to VanEck Pharmaceutical etf.
VanEck |
VanEck Pharmaceutical ETF ETF Price To Earning Analysis
VanEck Pharmaceutical's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current VanEck Pharmaceutical Price To Earning | 17.83 X |
Most of VanEck Pharmaceutical's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VanEck Pharmaceutical ETF is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, VanEck Pharmaceutical ETF has a Price To Earning of 17.83 times. This is much higher than that of the VanEck family and significantly higher than that of the Health category. The price to earning for all United States etfs is notably lower than that of the firm.
VanEck Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VanEck Pharmaceutical's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of VanEck Pharmaceutical could also be used in its relative valuation, which is a method of valuing VanEck Pharmaceutical by comparing valuation metrics of similar companies.VanEck Pharmaceutical is currently under evaluation in price to earning as compared to similar ETFs.
Fund Asset Allocation for VanEck Pharmaceutical
The fund invests 99.86% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides VanEck Pharmaceutical's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
VanEck Fundamentals
| Price To Earning | 17.83 X | |||
| Price To Book | 2.74 X | |||
| Price To Sales | 1.14 X | |||
| Beta | 0.61 | |||
| Market Capitalization | 877.34 M | |||
| Total Asset | 530.46 M | |||
| One Year Return | 16.80 % | |||
| Three Year Return | 10.00 % | |||
| Five Year Return | 9.60 % | |||
| Ten Year Return | 5.10 % | |||
| Net Asset | 530.46 M | |||
| Last Dividend Paid | 0.35 | |||
| Equity Positions Weight | 99.86 % |
About VanEck Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VanEck Pharmaceutical ETF's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VanEck Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VanEck Pharmaceutical ETF based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether VanEck Pharmaceutical ETF offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VanEck Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vaneck Pharmaceutical Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Vaneck Pharmaceutical Etf:Check out VanEck Pharmaceutical Piotroski F Score and VanEck Pharmaceutical Altman Z Score analysis. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
The market value of VanEck Pharmaceutical ETF is measured differently than its book value, which is the value of VanEck that is recorded on the company's balance sheet. Investors also form their own opinion of VanEck Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is VanEck Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VanEck Pharmaceutical's market value can be influenced by many factors that don't directly affect VanEck Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VanEck Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if VanEck Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VanEck Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.